MaxCyte, Inc. New Maryland headquarters
September 21 2022 - 8:05AM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
21 September 2022
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland's
I-270 Biotech Corridor
Expanded facilities illustrate MaxCyte's commitment to
Montgomery County and the state of Maryland, building the life
sciences community, and propelling local job opportunities.
ROCKVILLE, MD, September 21, 2022 -- MaxCyte, Inc. , (Nasdaq:
MXCT; LSE: MXCT), a leading commercial cell-engineering company
focused on providing enabling platform technologies to advance
innovative cell-based research, as well as next-generation cell
therapeutic discovery, development and commercialization, today
announced that it has relocated its headquarters to 9713 Key West
Avenue in Rockville, Maryland, 20850, within Maryland's I-270
Biotech Corridor. The Company's new 67,000 square -foot facility
significantly increases its in-house manufacturing capacity, as
well as research and process development lab space. This investment
represents a major milestone in MaxCyte's growth and its ability to
support customers and partners in their journey through therapeutic
development to commercialization.
"The State of Maryland and Montgomery County have worked
relentlessly over several decades to cultivate a robust life
sciences and biotech community, with MaxCyte playing a critical
role in that development," said Doug Doerfler, President and CEO of
MaxCyte. "During the past 20 years, MaxCyte has pioneered
cell-engineering technology and is now at the forefront, driving a
new generation of cell-based therapies, particularly in gene
editing and immuno-oncology. As we continue our work toward
transforming patients' lives globally, we remain committed to
fearless innovation and scientific solutions that help our partners
discover and develop life-saving therapeutics through the
application of our unmatched technology platforms paired with
outstanding support and expertise."
This new facility, with expanded lab and manufacturing spaces
will enable MaxCyte to support the growing needs of our partners as
they move their therapeutic programs through clinical development
to approval and commercialization. Building out these advanced
capabilities will also enable the Company to continue our expansion
into new research areas and applications for our use of our
technology.
"We believe strongly in creating an environment where employees
know that we are in this together and that their efforts,
individually and as a team, are contributing to MaxCyte's success
and ultimately, delivering new therapeutics to patients. We want
all of our employees to feel valued and to be empowered to make a
difference," said Jill Mayer, Vice President of Talent and Teamwork
at MaxCyte.
According to CBRE's I-270 Biotech Corridor: 2021 Year-End Report
, Maryland is the fifth largest biotech hub in the US and is
experiencing significant and rapid growth due to the influx of
public and private sector funding. Maryland ranked first in the
Milken Institute's 2020 State Technology and Science Index
technology and science workforce subindex and second in the
research and development sub-index, with the highest levels of
federal government and academic funding for R&D of any state.
Rockville is at the center of the I-270 Biotech Corridor and its
Economic Development partnership boasts more than 10,000 bio health
workers in the private sector, 49,000 in federal government
agencies, and 150+ life sciences companies with a Rockville
address, not to mention its close proximity to the National
Institutes of Health, US Food and Drug Administration, and other
Federal and academic institutions.
"We are excited for the future and see our move to this new
facility as a milestone in MaxCyte's growth and the expansion of
the region's biotech community," said Mr. Doerfler. " We are here
to help save lives. That's what drives us to innovate and make our
partners successful."
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: three instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. Learn more at
maxcyte.com and follow us on Twitter and LinkedIn .
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
jr@maxcyte.com
US Media Relations
Seismic Collaborative, A Spectrum Science Company
Valerie Enes
+1 408-497-8568
valerie@teamseismic.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPUPABUPPURG
(END) Dow Jones Newswires
September 21, 2022 08:05 ET (12:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024